Prevalence and number of B-cell subsets (MZB vs FOB)
| . | WT . | PARP-14 KO . |
|---|---|---|
| % of MZB* | 9.9 ± 0.6 | 5.1 ± 0.8† |
| % of FOB* | 63 ± 2.9 | 79 ± 2.5† |
| No. of MZB ( × 106)* | 3.4 ± 0.62 | 2.0 ± 0.86† |
| No. of FOB ( × 106)* | 20.8 ± 2.0 | 26.4 ± 3.7‡ |
| . | WT . | PARP-14 KO . |
|---|---|---|
| % of MZB* | 9.9 ± 0.6 | 5.1 ± 0.8† |
| % of FOB* | 63 ± 2.9 | 79 ± 2.5† |
| No. of MZB ( × 106)* | 3.4 ± 0.62 | 2.0 ± 0.86† |
| No. of FOB ( × 106)* | 20.8 ± 2.0 | 26.4 ± 3.7‡ |
Data shown as mean (± SEM) percentage or number of cells from the 3 independent replicate experiments. MZB indicates marginal zone B cells; FOB, follicular B cells.
Total splenocytes were isolated, gated for B220+ cells, and analyzed for percentage or number of MZB (CD23hi CD21hi) or FOB (CD23lo CD21hi).
Significant difference between WT and PARP-14 KO mice (P < .01).
Significant difference between WT and PARP-14 KO mice (P < .05).